Skip to main content

Table 1 Baseline characteristics, treatment, and effects of treatment in AAV patients

From: Longitudinal immune cell monitoring identified CD14++ CD16+ intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis

Variable

AAV, n = 29

Induction treatment

HC, n = 18

IVCY, n = 10

RTX, n = 8

Others, n = 11

Baseline demographic

 Age at diagnosis, years

70 (57–79)

68 (52–75)

61 (50–76)

79 (64–83)

51 (46–60)

 Male, n (%)

13 (45)

6 (60)

2 (25)

5 (45)

7 (39)

 PR3-ANCA+ GPA, n (%)

7 (24)

3 (30)

2 (25)

2 (18)

 

 MPO-ANCA+ GPA, n (%)

5 (17)

2 (20)

1 (13)

2 (18)

 ANCA− GPA, n (%)

1 (3)

0 (0)

1 (13)

0 (0)

 MPO-ANCA+ MPA, n (%)

16 (55)

5 (50)

4 (50)

7 (64)

 BVAS

12 (8.5–15)

12 (12–17)

9 (9–16)

10 (5–14)

Organ involvement

 Ear, nose, throat, n (%)

13 (45)

5 (50)

3 (38)

5 (45)

 

 CNS, n (%)

7 (24)

2 (20)

3 (38)

2 (18)

 PNS, n (%)

5 (17)

1 (10)

2 (25)

2 (18)

 Kidney, n (%)

12 (41)

5 (50)

3 (38)

4 (36)

 ILD, n (%)

17 (59)

5 (50)

4 (50)

8 (73)

Laboratory tests

 ESR, mm/h

102 (47–124)

105 (93–123)

53 (17–119)

121 (61–128)

 

 WBC, × 103 cells/μL

9.2 (7.0–14)

14 (8.7–15)

8.3 (5.4–9.0)

9.2 (6.1–15)

 Hemoglobin, g/dL

11 (10–13)

11 (8.7–12)

13 (9.9–15)

11 (10–12)

 Platelet, × 104 cells/μL

33 (25–41)

38 (28–41)

29 (20–35)

32 (26–49)

 CRP, mg/dL

5.5 (1.2–9.4)

8.5 (3.8–13)

1.1 (0.3–7.7)

5.5 (4.4–8.3)

 IgG, g/dL

1.8 (1.3–2.0)

1.8 (1.2–2.0)

1.6 (0.9–2.1)

1.8 (1.5–2.2)

 RF, IU/L

56 (21–146)

43 (8.8–146)

33 (23–143)

65 (37–301)

 MPO/PR3-ANCA, IU/L

48 (17–189)

44 (17–300)

40 (9.5–82)

77 (25–221)

PSL dose

 Initial PSL dose, mg/day

45 (33–60)

59 (45–63)

43 (30–59)

40 (30–50)

 

 PSL dose at week 24, mg/day

11 (10–16)

14 (10–33)

11 (7.6–12)

13 (10–16)

 PSL dose at week 52, mg/day

8 (6–11)

9 (5.5–16)

8 (4.5–9.3)

8 (6–14)

Maintenance therapy

AZA, 12 (41); RTX, 6 (21); MTX, 2 (7); Tac, 2 (7)

AZA. 5 (50); Tac, 2 (20)

RTX, 6 (75)

AZA, 7 (64); MTX, 2 (18)

Outcome

 Relapse, n (%)

10 (34)

3 (30)

3 (38)

3 (27)

 

 Severe infection, n (%)

10 (34)

5 (50)

2 (25)

3 (27)

 Death, n (%)

2 (7)

1 (10)

0 (0)

1 (9)

  1. Continuous data are expressed as median (IQR), and categorical data as number and/or percentage. AAV ANCA-associated vasculitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, WBC white blood cell, CRP C-reactive protein, RF rheumatoid factor, PSL prednisolone, IVCY intravenous cyclophosphamide, RTX rituximab, AZA azathioprine, MTX methotrexate, Tac tacrolimus
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us